KK, Leong D, O'Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. \[[PMC free article: PMC8006904](/pmc/articles/PMC8006904/)\] \[[PubMed: 31492503](https://pubmed.ncbi.nlm.nih.gov/31492503)\] 28. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. \[[PubMed: 16443044](https://pubmed.ncbi.nlm.nih.gov/16443044)\] 29. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. \[[PubMed: 22227365](https://pubmed.ncbi.nlm.nih.gov/22227365)\] 30. Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. \[[PMC free article: PMC4448074](/pmc/articles/PMC4448074/)\] \[[PubMed: 26779498](https://pubmed.ncbi.nlm.nih.gov/26779498)\] 31. Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. \[[PMC free article: PMC9553007](/pmc/articles/PMC9553007/)\] \[[PubMed: 36237903](https://pubmed.ncbi.nlm.nih.gov/36237903)\] 32. Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. \[[PMC free article: PMC7428996](/pmc/articles/PMC7428996/)\] \[[PubMed: 32427034](https://pubmed.ncbi.nlm.nih.gov/32427034)\] 33. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. \[[PMC free article: PMC8837825](/pmc/articles/PMC8837825/)\] \[[PubMed: 33004114](https://pubmed.ncbi.nlm.nih.gov/33004114)\] 34. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. \[[PMC free article: PMC6899218](/pmc/articles/PMC6899218/)\] \[[PubMed: 31202759](https://pubmed.ncbi.nlm.nih.gov/31202759)\] 35. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. \[[PMC free article: PMC4654630](/pmc/articles/PMC4654630/)\] \[[PubMed: 26250359](https://pubmed.ncbi.nlm.nih.gov/26250359)\] 36. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. \[[PMC free article: PMC5734941](/pmc/articles/PMC5734941/)\] \[[PubMed: 28560717](https://pubmed.ncbi.nlm.nih.gov/28560717)\] 37. King M, Kingery